Congenital clubfoot in Europe: A population-based study.
associated anomalies
congenital lubfoot
prenatal diagnosis
prevalence
trend
Journal
American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
07
09
2018
revised:
13
01
2019
accepted:
17
01
2019
pubmed:
12
2
2019
medline:
23
4
2020
entrez:
12
2
2019
Statut:
ppublish
Résumé
We aimed to assess prevalence, birth outcome, associated anomalies and prenatal diagnosis of congenital clubfoot in Europe using data from the EUROCAT network, and to validate the recording of congenital clubfoot as a major congenital anomaly by EUROCAT registries. Cases of congenital clubfoot were included from 18 EUROCAT registries covering more than 4.8 million births in 1995-2011. Cases without chromosomal anomalies born during 2005-2009, were randomly selected for validation using a questionnaire on diagnostic details and treatment. There was 5,458 congenital clubfoot cases of which 5,056 (93%) were liveborn infants. Total prevalence of congenital clubfoot was 1.13 per 1,000 births (95% CI 1.10-1.16). Prevalence of congenital clubfoot without chromosomal anomaly was 1.08 per 1,000 births (95% CI 1.05-1.11) and prevalence of isolated congenital clubfoot was 0.92 per 1,000 births (95% CI 0.90-0.95), both with decreasing trends over time and large variations in prevalence by registry. The majority of cases were isolated congenital clubfoot (82%) and 11% had associated major congenital anomalies. Prenatal detection rate of isolated congenital clubfoot was 22% and increased over time. Among 301 validated congenital clubfoot cases, diagnosis was confirmed for 286 (95%). In conclusion, this large population-based study found a decreasing trend of congenital clubfoot in Europe after 1999-2002, an increasing prenatal detection rate, and a high standard of coding of congenital clubfoot in EUROCAT.
Identifiants
pubmed: 30740879
doi: 10.1002/ajmg.a.61067
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-601Subventions
Organisme : European Commission under the Seventh Framework Programme through the key action
ID : HEALTH.2010.4.2 -3
Pays : International
Organisme : Adverse Drug Reaction Research
ID : 260598
Pays : International
Organisme : GlaxoSmithKline, 2007-2011 for staff time (Universities of Groningen and Ulster)
Pays : International
Organisme : Adverse Drug Reaction Research
ID : no. 260598
Pays : International
Informations de copyright
© 2019 Wiley Periodicals, Inc.